Skip to main content

Advertisement

Log in

Metabolic disorders: stones as first clinical manifestation of significant diseases

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Introduction

Metabolic syndrome, type 2 diabetes, and primary hyperparathyroidism are metabolic disorders that should deserve a special focus in renal stone patients as a pathogenic link is established with some stone components. Indeed, an acidic urinary pH due to a decreased ammonium bioavailability explains the high prevalence of uric acid stones in patients with metabolic syndrome or diabetes and, primary hyperparathyroidism induced hypercalciuria increases the risk of calcium phosphate stones.

Materials and methods

We report here four clinical cases of renal stone patients with metabolic disorders encountered in a daily practice. Clinical and metabolic findings altogether with stone analysis components presented here, illustrate relevant pathophysiological links.

Conclusion

24 hours urine evaluation and stone analysis which includes both morphological typing and infrared spectroscopy, are key diagnostic steps for early recognition of metabolic disorders. Metabolic screening allows diet related stone identification, points out stone risk factors and identifies patients’comorbidity. The occurrence of nephrocalcinosis with or without chronic renal failure should require a more detailed metabolic evaluation in order to identify uncommon etiologies such as renal tubular acidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS (2012) OxalEurope. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27(5):1729–1736

    Article  CAS  PubMed  Google Scholar 

  2. Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, Palacín M (2010) Pathophysiology and treatment of cystinuria. Nat Rev Nephrol 6(7):424–434

    Article  PubMed  Google Scholar 

  3. Bollée G, Dollinger C, Boutaud L, Guillemot D, Bensman A, Harambat J, Deteix P, Daudon M, Knebelmann B, Ceballos-Picot I (2010) Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J Am Soc Nephrol 21(4):679–688

    Article  PubMed Central  PubMed  Google Scholar 

  4. Daudon M (2005) Epidemiology of nephrolithiasis in France. Ann Urol (Paris) 39(6):209–231

    Article  CAS  Google Scholar 

  5. Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR (2014) Medical Management of Kidney Stones: AUA Guideline. J Urol, S0022: 5347

  6. Tiselius HG (2003) Epidemiology and medical management of stone disease. BJU Int 91(8):758–767

    Article  PubMed  Google Scholar 

  7. Daudon M, Bader CA (1993) Jungers P Urinary calculi: review of classification methods and correlations with etiology. Scanning Microsc 7(3):1081–1104

    CAS  PubMed  Google Scholar 

  8. Ramphal L, Zhang J, Suzuki S (2014) Ethnic disparities in the prevalence of the metabolic syndrome in American adults: data from the Examination of National Health and Nutrition Examination Survey 1999–2010. Proc Bayl Univ Med Cent 27(2):92–95

    PubMed Central  PubMed  Google Scholar 

  9. von Frankenberg AD, doNascimento FV, Gatelli LE, Nedel BL, Garcia SP, de Oliveira CS, Saddi-Rosa P, Reis AF, Canani LH, Gerchman F (2014) Major components of metabolicsyndrome and adiponectin levels: a cross-sectional study. Diabetol Metab Syndr 6(1):26

    Article  Google Scholar 

  10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

  11. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K (2004) The metabolicsyndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 65(2):386–392

    Article  CAS  PubMed  Google Scholar 

  12. Kohjimoto Y, Sasaki Y, Iguchi M, Matsumura N, Inagaki T, Hara I (2013) Association of metabolic syndrome traits and severity of kidney stones: results from a nationwide survey on urolithiasis in Japan. Am J Kidney Dis 61(6):923–929

    Article  PubMed  Google Scholar 

  13. Cho ST, Jung SI, Myung SC, Kim TH (2013) Correlation of metabolic syndrome with urinary stone composition. Int J Urol 20(2):208–213

    Article  CAS  PubMed  Google Scholar 

  14. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K (2007) Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol 2:883–888

    Article  CAS  PubMed  Google Scholar 

  15. Sakhaee K, Maalouf NM (2008) Metabolic syndrome and uric acid nephrolithiasis. Semin Nephrol 28(2):174–180

    Article  CAS  PubMed  Google Scholar 

  16. Daudon M, Jungers P (2007) Diabetes and nephrolithiasis. Curr Diab Rep 7(6):443–448

    Article  PubMed  Google Scholar 

  17. Cameron M, Maalouf NM, Poindexter J, Adams-Huet B, Sakhaee K, Moe OW (2012) The diurnal variation in urine acidification differs between normal individuals and uric acid stone formers. Kidney Int 81(11):1123–1130

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Li C, Hsieh MC, Chang SJ (2013) Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol 25(2):210–216

    Article  CAS  PubMed  Google Scholar 

  19. Fraile JM, Puig JG, Torres RJ, de Miguel E, Martínez P, Vázquez JJ (2010) Uric acid metabolism in patients with primary gout and the metabolic syndrome. Nucleosides Nucleotides Nucleic Acids 29(4–6):330–334

    Article  CAS  PubMed  Google Scholar 

  20. Daudon M, Traxer O, Conort P, Lacour B, Jungers P (2006) Type 2 diabetes increases the risk for uric acidstones. J Am Soc Nephrol 17(7):2026–2033

    Article  CAS  PubMed  Google Scholar 

  21. Lieske JC, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton LJ III, Leibson CL (2006) Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis 48(6):897–904

    Article  PubMed  Google Scholar 

  22. Pak CY, Sakhaee K, Moe O, Preminger GM, Poindexter JR, Peterson RD, Pietrow P, Ekeruo W (2003) Biochemical profile of stone-forming patients with diabetes mellitus. Urology 61(3):523–527

    Article  PubMed  Google Scholar 

  23. Rejnmark L, Vestergaard P, Mosekilde L (2011) Nephrolithiasis and renal calcifications in primary hyperparathyroidism. J Clin Endocrinol Metab 96(8):2377–2385

    Article  CAS  PubMed  Google Scholar 

  24. Suh JM, Cronan JJ, Monchik JM (2008) Primary hyperparathyroidism: is there an increased prevalence of renal stone disease? Am J Roentgenol 191(3):908–911

    Article  Google Scholar 

  25. Daudon M, Bouzidi H, Bazin D (2010) Composition and morphology of phosphate stones and their relation with etiology. Urol Res 38(6):459–467

    Article  CAS  PubMed  Google Scholar 

  26. Krambeck AE, Handa SE, Evan AP, Lingeman JE (2010) Brushite stone disease as a consequence of lithotripsy? Urol Res 38(4):293–299

    Article  PubMed Central  PubMed  Google Scholar 

  27. DeLellis RA, Mazzaglia P, Mangray S (2008) Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med 8:1251–1262

    Google Scholar 

  28. Nakaoka D, Sugimoto T, Kobayashi T, Yamaguchi T, Kobayashi A, Chihara K (2000) Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 85(5):1901–1907

    CAS  PubMed  Google Scholar 

  29. Bruce LJ, Cope DL, Jones GK, Schofield AE, Burley M, Povey S, Unwin RJ, Wrong O, Tanner MJ (1997) Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. J Clin Invest 100(7):1693–1707

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Melton LJ III, Crowson CS, Khosla S, Wilson DM, O’Fallon WM (1998) Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int 53(2):459–464

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We do thank Dr. Michel Daudon for helpful comments and critical review of the manuscript.

Conflict of interest

None.

Ethical standard

The patients described in the case reports of this manuscript gave an informed consent.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jean-Philippe Haymann.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haymann, JP. Metabolic disorders: stones as first clinical manifestation of significant diseases. World J Urol 33, 187–192 (2015). https://doi.org/10.1007/s00345-014-1391-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1391-5

Keywords

Navigation